Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bayer/Merck Cardiovascular Drug Approved for China Use

publication date: May 19, 2022

Germany’s Bayer AG and Merck/MSD were approved to launch a novel cardiovascular drug in China. Verquvo™ (vericiguat) is a soluble guanylate cyclase (sGC) stimulator that is indicated to reduce the risk of hospitalization or IV diuretics in patients with symptomatic chronic HF and reduced ejection fraction. Patients are prescribed the drug following a decompensation event. Verquvo’s novel mechanism restores the deficient NO-sGC-cGMP pathway, which plays a critical role in the progression of heart failure by aggravating its symptoms. Verquvo was approved as an addition to standard-of-care. More details....

Stock Symbols: (XE: BAYN) (NYSE: MRK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital